HRGN

Harvard Apparatus Regenerative Technology Inc.

HRGN, USA

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product candidates to treat conditions of the esophagus, including traumatic injury, caustic burns, tissue damage following chemoradiation therapy, birth defects, and reconstruction of the colon and uterus wound repair. It also sells consumer health products that focuses on personal healthcare, including dietary supplements. Harvard Apparatus Regenerative Technology Inc. was formerly known as Biostage, Inc. and changed its name to Harvard Apparatus Regenerative Technology Inc. in July 2023. The company was founded in 2009 and is headquartered in Holliston, Massachusetts.

https://hregen.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
HRGN
stock
HRGN

Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease marketscreener.com

Read more →
HRGN
stock
HRGN

Harvard Apparatus Regenerative Tech Announces Private Stock Placement TipRanks

Read more →

Showing 2 of 3

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

20.99

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-109.40 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-66.77 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-1,191.06 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Medium

0.64

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Harvard Apparatus Regenerative Technology Inc.

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0

Latest Release

Date

2025-09-30

EPS Actual

-0.1

EPS Estimate

0

EPS Difference

-0.1

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.